Tatva Chintan Pharma Chem Limited will conduct a virtual one-to-one interaction with Mahindra Manulife Investment Management Private Limited on August 06, 2026. The company filed the intimation with the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on August 03, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This engagement allows institutional investors to engage with management using only publicly available data, ensuring transparency and adherence to regulatory guidelines regarding unpublished price-sensitive information (UPSI).

Ishwar Ramanbhai Nayi, Company Secretary and Compliance Officer of Tatva Chintan Pharma, signed the submission confirming the schedule. The filing replaces an earlier intimation that listed a different participant, reflecting the final confirmed agenda for the upcoming session.

Meeting Details

The interaction is structured as a focused dialogue between the company's representatives and the selected financial institution. The session will be conducted virtually, ensuring accessibility without geographical constraints.

Regulatory Compliance and Information Scope

Management emphasized that the discussion will be confined to information already in the public domain. No confidential or unpublished price-sensitive information will be shared during the interaction, aligning with standard compliance protocols for such meetings. Any updates or changes to the schedule will be communicated promptly, with all relevant information made available on the company’s official website at www.tatvachintan.com .

What the Numbers Show

While this filing does not contain new financial metrics, the decision to host a dedicated one-to-one session with Mahindra Manulife Investment Management signals active investor relations efforts. By restricting the scope to publicly available information, the company reinforces its commitment to equal information access, preventing any selective disclosure advantages while keeping institutional investors updated on strategic directions already known to the market.

Tatva Chintan Pharma Chem Limited will host a virtual one-to-one analyst meeting with Tamohara Investment Managers Pvt. Ltd. on July 30, 2026. The company disclosed the engagement schedule to the Bombay Stock Exchange and National Stock Exchange of India Limited on July 24, 2026, in compliance with market transparency norms. This interaction provides investors and financial institutions an opportunity to discuss the company’s operational and financial performance based on existing public disclosures.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ishwar Nayi, Company Secretary and Compliance Officer of Tatva Chintan Pharma Chem Limited, signed the intimation letter submitted to the exchanges. The company emphasized that the meeting schedule is subject to change if necessary.

Meeting Details

Information Scope

Tatva Chintan Pharma Chem Limited stated that it will refer only to publicly available information during the interaction. The company explicitly confirmed that no confidential or unpublished price sensitive information (UPSI) will be shared during the meeting. This ensures compliance with insider trading regulations while facilitating investor dialogue.

The details of the meeting and related disclosures are available on the company’s website at www.tatvachintan.com for public reference.